Diagnosis of hepatitis C virus infection by enzyme-linked immunosorbent assay and reverse transcriptase-nested polymerase chain reaction: a comparative evaluation.

Department of Biochemistry, Genetic Engineering and Biotechnology Research Division, National Research Center, Dokki, Giza, Egypt.
International Union of Biochemistry and Molecular Biology Life (Impact Factor: 2.79). 06/2011; 63(6):430-4. DOI: 10.1002/iub.469
Source: PubMed

ABSTRACT Hepatitis C virus is one of the main causes of chronic hepatitis in developing countries. The current study was to evaluate the efficacy of the enzyme-linked immunosorbent assay third generation (ELISA-3) for detection of antibodies to hepatitis C virus (anti-HCV) in comparison with reverse transcriptase-nested polymerase chain reaction (RT-nested PCR) to detect HCV RNA for the diagnosis of hepatitis C virus. Serum samples were collected from 151 chronic hepatitis C patients and 50 healthy individuals. All samples were tested for anti-HCV antibodies using ELISA-3 and HCV RNA by RT-nested PCR. Of the 151,120 (78.9%) were found to be seropositive by ELISA-3, and 148 (98%) patients were HCV RNA positive, 118 (78.1%) were positives for both, 30 (19.9%) were positive for ELISA-3 and negative for RT-PCR, and 2 cases (1.3%) were positive for RT-nested PCR and negative for ELISA-3. The sensitivity and the specificity for the detection of HCV were absolute when the two techniques were combined. In conclusion, ELISA-3 is a suitable assay for routine screening for anti-HCV. RT-nested PCR for HCV is a value for the early detection of viremic, anti-HCV negative cases; this may be of importance in treatment of hepatitis C.

  • [Show abstract] [Hide abstract]
    ABSTRACT: The origin of the hepatitis C virus (HCV) epidemic in Egypt has been attributed to intravenous schistosomiasis treatment in rural areas in the 1960s to 70s. The objective of this study was to estimate the HCV-related morbidity in a rural area where mass schistosomiasis treatment campaigns took place 20-40 years before. The study sample included 2,425 village residents aged 18-65 years recruited through home-based visits. Overall, HCV antibody prevalence was 448/2,425 = 18.5% (95% CI = 16.9-20.1%), reaching 45% in males over 40 years, and 30% in females over 50 years. Of those with HCV antibodies, 284/448 (63.4%, 95% CI = 58.7-67.9%) had chronic HCV infection, among which 107/266 (40.2%, 95% CI = 34.3-46.4%) had elevated alanine aminotransferase (ALT). As part of pre-treatment screening, 26 consenting patients had a liver biopsy: 13 (50.0%) had a treatment indication. Thus, of all patients with HCV antibodies, 13 (2.9%) were eligible for treatment and willing to be treated. The relatively low level of morbidity observed in this study is discussed in view of co-factors of HCV infection progression, such as young age at infection, absence of alcohol intake, the prevalence of Schistosoma mansoni infection, and the prevalence of chronic hepatitis B.
    Journal of Medical Virology 10/2006; 78(9):1185-9. · 2.37 Impact Factor